Literature DB >> 20385902

Clearance of mutant proteins as a therapeutic target in neurodegenerative diseases.

Dimitri Krainc1.   

Abstract

Accumulation and aggregation of disease-causing proteins is a hallmark of several neurodegenerative disorders such as Parkinson, Alzheimer, and Huntington diseases. One of the main goals of research in neurodegenerative disorders has been to improve clearance of these accumulated proteins. Using the example of Huntington disease, I discuss strategies to selectively activate cellular degradation machinery to improve clearance of the mutant protein and to identify therapeutic targets for the treatment of Huntington disease and related neurodegenerative disorders.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20385902     DOI： 10.1001/archneurol.2010.40

Source DB:  PubMed          Journal:  Arch Neurol        ISSN： 0003-9942


  16 in total

Review 1.  The importance of integrating basic and clinical research toward the development of new therapies for Huntington disease.

Authors:  Ignacio Munoz-Sanjuan; Gillian P Bates
Journal:  J Clin Invest       Date:  2011-02-01       Impact factor: 14.808

2.  Systemic isradipine treatment diminishes calcium-dependent mitochondrial oxidant stress.

Authors:  Jaime N Guzman; Ema Ilijic; Ben Yang; Javier Sanchez-Padilla; David Wokosin; Dan Galtieri; Jyothisri Kondapalli; Paul T Schumacker; D James Surmeier
Journal:  J Clin Invest       Date:  2018-04-30       Impact factor: 14.808

Review 3.  Metabolism as a key to histone deacetylase inhibition.

Authors:  Praveen Rajendran; David E Williams; Emily Ho; Roderick H Dashwood
Journal:  Crit Rev Biochem Mol Biol       Date:  2011-04-05       Impact factor: 8.250

Review 4.  Pathways to neurodegeneration: mechanistic insights from GWAS in Alzheimer's disease, Parkinson's disease, and related disorders.

Authors:  Vijay K Ramanan; Andrew J Saykin
Journal:  Am J Neurodegener Dis       Date:  2013-09-18

5.  Autophagy, mitochondria and 3-nitropropionic acid joined in the same model.

Authors:  Rosa A González-Polo; José M Bravo-San Pedro; Rubén Gómez-Sánchez; Elisa Pizarro-Estrella; Mireia Niso-Santano; José M Fuentes
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

Review 6.  Development of targeted therapies for Parkinson's disease and related synucleinopathies.

Authors:  Edmund Sybertz; Dimitri Krainc
Journal:  J Lipid Res       Date:  2014-03-25       Impact factor: 5.922

7.  Automated high-content live animal drug screening using C. elegans expressing the aggregation prone serpin α1-antitrypsin Z.

Authors:  Sager J Gosai; Joon Hyeok Kwak; Cliff J Luke; Olivia S Long; Dale E King; Kevin J Kovatch; Paul A Johnston; Tong Ying Shun; John S Lazo; David H Perlmutter; Gary A Silverman; Stephen C Pak
Journal:  PLoS One       Date:  2010-11-12       Impact factor: 3.240

8.  Changing scenario of neuropractice.

Authors:  Me Yeolekar
Journal:  J Neurosci Rural Pract       Date:  2011-01

9.  Nemo-like kinase reduces mutant huntingtin levels and mitigates Huntington's disease.

Authors:  Mali Jiang; Xiaoyan Zhang; Hongshuai Liu; Jared LeBron; Athanasios Alexandris; Qi Peng; Hao Gu; Fanghan Yang; Yuchen Li; Ruiling Wang; Zhipeng Hou; Nicolas Arbez; Qianwei Ren; Jen-Li Dong; Emma Whela; Ronald Wang; Tamara Ratovitski; Juan C Troncoso; Susumu Mori; Christopher A Ross; Janghoo Lim; Wenzhen Duan
Journal:  Hum Mol Genet       Date:  2020-05-28       Impact factor: 6.150

10.  ENC1 Modulates the Aggregation and Neurotoxicity of Mutant Huntingtin Through p62 Under ER Stress.

Authors:  Huikyong Lee; Hye-Hyun Ahn; WonJae Lee; Yumin Oh; Hyunwoo Choi; Sang Mi Shim; Jaekyoon Shin; Yong-Keun Jung
Journal:  Mol Neurobiol       Date:  2015-12-05       Impact factor: 5.682
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.